Mannitol inhalation - Pharmaxis

Drug Profile

Mannitol inhalation - Pharmaxis

Alternative Names: Bronchitol; Mannitol dry powder for inhalation - Pharmaxis; Precision spray‐dried mannitol

Latest Information Update: 18 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Royal Prince Alfred Hospital
  • Developer Pharmaxis
  • Class Diagnostic agents; Small molecules; Sugar alcohols
  • Mechanism of Action Osmotic diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis; Cystic fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes - Bronchiectasis; Cystic fibrosis

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase III Bronchiectasis
  • Discontinued Allergic rhinitis; Sinusitis

Most Recent Events

  • 13 Jun 2017 Pharmaxis announces intention to resubmit NDA to US FDA in 2018
  • 13 Jun 2017 Efficacy and adverse events data from a pivotal phase III trial in Cystic fibrosis released by Pharmaxis
  • 13 Jun 2017 Pharmaxis completes a pivotal phase III trial in Cystic fibrosis (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top